Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Shari Brazinsky

Pulmonary Disease San Diego, CA Medical Doctor

NPI 1245339340 CMS profile 101189

3110 Camino Del Rio S, San Diego, CA 92108

Open in the dashboard

General payments

$82,214

418 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$439,786 paid to institutions, not to them · program years 2019–2024

Through program year 2023, Shari Brazinsky of San Diego, CA is reported in the CMS Open Payments database as having received $82,214 across 418 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $439,786 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $8,053 20
2022 General $35,893 113
2021 General $12,468 92
2020 General $16,241 80
2019 General $9,558 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shari Brazinsky
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Shari Brazinsky were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Shari Brazinsky Pulmonary Disease median Middle half National median
2019 $9,558 $377 $109–$1,340 $163
2020 $16,241 $230 $56–$907 $114
2021 $12,468 $269 $68–$1,072 $132
2022 $35,893 $390 $100–$1,457 $149
2023 $8,053 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. GlaxoSmithKline, LLC. $74,217 101 payments
  2. AstraZeneca Pharmaceuticals LP $2,216 50 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $967 49 payments
  4. Regeneron Healthcare Solutions, Inc. $783 28 payments
  5. Amgen Inc. $653 5 payments
  6. Actelion Pharmaceuticals US, Inc. $444 30 payments
  7. Genzyme Corporation $378 19 payments
  8. Merck Sharp & Dohme Corporation $318 14 payments
  9. Pfizer Inc. $232 13 payments
  10. Insmed, Inc. $229 11 payments
  11. Other $1,777 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $68,823 39 payments
  2. Food and Beverage $8,028 356 payments
  3. Travel and Lodging $4,519 13 payments
  4. Consulting Fee $645 2 payments
  5. Education $171 6 payments
  6. Gift $28 2 payments
Products named General payments · program years 2019–2023
  1. TRELEGY ELLIPTA $52,663 53 payments
  2. ANORO ELLIPTA $2,497 7 payments
  3. BEVESPI AEROSPHERE $1,289 4 payments
  4. DUPIXENT Inflammation And Immunology $783 28 payments
  5. SPIRIVA RESPIMAT $672 43 payments
  6. OFEV $468 25 payments
  7. UPTRAVI $444 30 payments
  8. OPSUMIT $399 28 payments
  9. DUPIXENT Immunology $340 17 payments
  10. NUCALA $338 15 payments
  11. Other $5,290 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

418 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record